Comprehensive analysis of the efficacy and effects of Serputinib/Serpatinib (Ruitu)

Selpercatinib is an oral small molecule targeted drug targeting RET gene abnormalities and is considered one of the representative drugs for precision treatment of the RET pathway. RET gene mutations or fusions are common in some non-small cell lung cancer (NSCLC), thyroid cancer, medullary thyroid cancer and other solid tumors, and Seputinib is an innovative drug specially developed for such patients. Its main mechanism of action is to selectively inhibit the abnormal signaling of RET kinase, thereby blocking the growth and spread of tumor cells. This mechanism enables it to show significant clinical effects in the treatment of RET fusion-positive or mutation-positive tumors.

Unlike traditional chemotherapy or radiotherapy, Seputinib has the characteristics of high selectivity and low off-target, and can accurately target RET mutation sites, reducing the impact on normal cells, thereby significantly reducing the risk of adverse reactions. This characteristic allows patients to generally achieve better tolerance and quality of life during treatment. A number of foreign real-world usage data also show that Septinib has stable performance in controlling disease progression and prolonging survival time. Especially for patients who have received multiple lines of treatment in the past, Septinib can still exert a sustained anti-tumor effect.

In terms of usage, seputinib is administered orally, and the recommended dose can be adjusted individually by a doctor based on body weight or condition. Its metabolism is mainly through the liver's CYP3A enzyme system, so patients need to avoid combining it with strong CYP3A inhibitors or inducers during use to prevent abnormal increases or decreases in drug concentration. Some patients may experience mild to moderate side effects, such as dry mouth, fatigue, increased blood pressure, or changes in liver function indicators, but most adverse reactions can be controlled by temporary discontinuation of the drug or dose adjustment.

The clinical value of Seputinib is not only reflected in its efficacy, but also represents a new trend in precision tumor treatment. After clarifying the RET mutation status through genetic testing, doctors can develop more personalized targeted treatment plans for patients, greatly improving treatment efficiency and safety.

Reference:https://en.wikipedia.org/wiki/Selpercatinib